Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

β-adrenergic receptor agonists/Corticosteroids/Omalizumab

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Zamparelli SS, et al. Antibodies Anti-Benralizumab: A Suggestive Mechanism of Resistance to this Biological Drug. Respiration 102: 726-727 abstr. 157, No. 8, Sep 2023. Available from: URL: https://dx.doi.org/10.1159/000531211 [abstract] Zamparelli SS, et al. Antibodies Anti-Benralizumab: A Suggestive Mechanism of Resistance to this Biological Drug. Respiration 102: 726-727 abstr. 157, No. 8, Sep 2023. Available from: URL: https://dx.doi.org/10.1159/000531211 [abstract]
Metadaten
Titel
β-adrenergic receptor agonists/Corticosteroids/Omalizumab
Lack of efficacy
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-50245-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Paclitaxel

Case report

Thiamazole

Case report

Tenecteplase

Case report

Multiple drugs

Case report

Pembrolizumab

Case report

Nivolumab